Research progress on the role of forkhead box protein M1 in brain glioma

doi:10.16352/j.issn.1001-6325.2023.10.1604

Abstract

Abstract: Glioma is the most common primary tumor found in central nervous system of adult patients. The forkhead box protein M1 (FOXM1) is a member of the forkhead box transcription factor family, which can regulate Wnt/β-Catenin, Akt/FOXM1, p53 pathways and their own post-translational modification processes promote the malignant proliferation, migration, and invasion of glioma. These results of research provide new theoretical basis and therapeutic targets for the clinical treatment of glioma.

Key words: forkhead box protein M1(FOXM1), glioma, Wnt/β-catenin, Akt/FOXM1, p53 pathway

CLC Number:

R730.264

HOU Xinran, HOU Jingya, ZHANG Yaru, LI Haili. Research progress on the role of forkhead box protein M1 in brain glioma[J]. Basic & Clinical Medicine, 2023, 43(10): 1604-1607.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.10.1604

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I10/1604

References

[1]Klinhom-On N, Seubwai W, Sawanyawisuth K, et al. FOXM1c is the predominant FOXM1 isoform expressed in cholangiocarcinoma that associated with metastatic poten-tial and poor prognosis of patients[J]. Heliyon, 2021, 7: e06846.doi: 10.1016/j.heliyon.2021.e06846.
[2]Shim JK, Lim SH, Jeong JH, et al. A lignan from Alnus japonica inhibits glioblastoma tumorspheres by suppression of FOXM1[J]. Sci Rep, 2022, 12: 13990.doi: 10.1038/s41598-022-18185-w.
[3]Patel AJ, Wan YW, Al-Ouran R, et al. Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors[J]. Proc Natl Acad Sci U S A, 2019, 116: 21715-21726.
[4]Yi L, Wang H, Li W, et al. The FOXM1/RNF26/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer[J]. Cell Death Dis, 2021, 12: 944.doi: 10.1038/s41419-021-04260-z.
[5]Uxa S, Castillo-Binder P, Kohler R, et al. Ki-67 gene expression[J]. Cell Death Differ, 2021, 28: 3357-3370.
[6]Fu J, Peng J, and Tu G Knockdown MTDH inhibits glioma proliferation and migration and promotes apoptosis by downregulating MYBL2[J]. Mediators Inflamm, 2022, 2022: 1706787.doi: 10.1155/2022/1706787.
[7]Zhao P, Li T, Wang Y, et al. LncRNA MYCNOS promotes glioblastoma cell proliferation by regulating miR-216b/FOXM1 axis[J]. Metab Brain Dis, 2021, 36: 1185-1189.
[8]Tao W, Zhang A, Zhai K, et al. SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expres-sion in glioma stem cells[J]. EMBO Mol Med, 2020, 12: e12291.doi: 10.15252/emmm.202012291.
[9]Sher G, Masoodi T, Patil K, et al. Dysregulated FOXM1 signaling in the regulation of cancer stem cells[J]. Semin Cancer Biol, 2022, 86: 107-121.
[10]Zhang N, Wei P, Gong A, et al. FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis[J]. Cancer Cell, 2011, 20: 427-42.
[11]Liu W, Shen D, Ju L, et al. MYBL2 promotes prolifera-tion and metastasis of bladder cancer through transactivation of CDCA3[J]. Oncogene, 2022, 41: 4606-4617.
[12]Chen L, Xu Z, Li Q, et al. USP28 facilitates pancreatic cancer progression through activation of Wnt/β-catenin pathway via stabilising FOXM1[J]. Cell Death Dis, 2021, 12: 887.doi: 10.1038/s41419-021-04163-z.
[13]Hashemi M, Etemad S, Rezaei S, et al. Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: revisiting molecular interactions[J]. Biomed Pharmacother, 2023, 158: 114204.doi: 10.1016/j.biopha.2022.114204.
[14]Xu K, Zhang K, Ma J, et al. CKAP4-mediated activation of FOXM1 via phosphorylation pathways regulates malig-nant behavior of glioblastoma cells[J]. Transl Oncol, 2023, 29: 101628.doi: 10.1016/j.tranon.2023.101628.
[15]Kimura H, Sada R, Takada N, et al. The Dickkopf1 and FOXM1 positive feedback loop promotes tumor growth in pancreatic and esophageal cancers[J]. Oncogene, 2021, 40: 4486-4502.
[16]Fu Y, Bai C, Wang S, et al. AKT1 phosphorylates RBM17 to promote Sox2 transcription by modulating alternative splicing of FOXM1 to enhance cancer stem cell properties in colorectal cancer cells[J]. FASEB J, 2023, 37: e22707.doi: 10.1096/fj.202201255R.
[17]Zhang X, Lv QL, Huang YT, et al. Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma[J]. J Exp Clin Cancer Res, 2017, 36: 105.doi: 10.1186/s13046-017-0573-6.
[18]Levine AJ p53: 800 million years of evolution and 40 years of discovery[J]. Nat Rev Cancer, 2020, 20: 471-480.
[19]Kennedy MC, Lowe SW. Mutant p53: it's not all one and the same[J]. Cell Death Differ, 2022, 29: 983-987.
[20]Kumari R, Hummerich H, Shen X, et al. Simultaneous expression of MMB-FOXM1 complex components enables efficient bypass of senescence[J]. Sci Rep, 2021, 11: 21506.doi: 10.1038/s41598-021-01012-z.
[21]Jia J, Cui Y, Tan Z, et al. Transcriptional factor FoxM1-activated microRNA-335-3p maintains the self-renewal of neural stem cells by inhibiting p53 signaling pathway via Fmr1[J]. Stem Cell Res Ther, 2021, 12: 169.doi: 10.1186/s13287-021-02191-2.
[22]Tanaka N, Zhao M, Tang L, et al. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1[J]. Oncogene, 2018, 37: 1279-1292.
[23]Zhang W, Qian W, Gu J, et al. Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer[J]. Cancer Lett, 2023, 552: 215976.doi: 10.1016/j.canlet.2022.215976.
[24]Bollu LR, Shepherd J, Zhao D, et al. Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1[J]. NPJ Breast Cancer, 2020, 6: 2.doi: 10.1038/s41523-019-0143-5.
[25]黄博, 程苾恒, 解美婷, 等. FOXM1促进子宫内膜癌细胞系HEC-1B增殖、迁移和侵袭[J]. 基础医学与临床, 2021, 41: 1780-1785.